This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Hoffman JP , Kusiak J , Boraas M , Genter B , Steuber K , Weese JL , Keidan RD , Eisenberg BL , Cox T , Litwin S
Risk-Factors for Immediate Prosthetic Postmastectomy Reconstruction
American Surgeon. 1991 Aug;57(8) :514-522
AbstractThe charts of 44 women who underwent 47 immediate postmastectomy prosthetic breast reconstructions (IPMPBR) with subpectoral prostheses (long-term implant, long-term expandable implant or tissue expanders followed by long-term prosthetic placement) were retrospectively reviewed. Follow-up was from 3 to 49 months (median 18 months). Patient ages ranged from 31 to 77 years (median 42) but 82 per cent were under 60 years old. Indications for mastectomy were infiltrating cancer in 30 patients, intraductal cancer in 11, lobular carcinoma in situ in two and prophylaxis in one. There were 11 patients with pathologic Stage I, 15 with Stage II, three with Stage III and one with Stage IV breast cancer. Adjuvant chemotherapy (CTX) was given to 17 women, adjuvant hormonal treatment to nine, and radiation therapy (RT) to five. One patient had prosthesis extrusion and removal. Two patients had late periprosthetic infections (PPI) with consequent prosthesis removal. CTX did not have a significant association with PPI (two of 14 with CTX vs 0 of 29 without, P = 0.1). However, fill port migrations, prosthesis deflations, and > 1 complication were significantly associated with these infections (two of three vs 0 of 38, P = 0.004; two of two vs 0 of 45, P = 0.001; two of four vs 0 of 43, P = 0.006). Skin flap cellulitis and postoperative seroma were also associated with PPI (P < 0.003 and < 0.006, respectively). These factors were all also significantly associated with involuntary prosthesis loss (n = 3). Seven of 30 prostheses were removed from patients with invasive cancer, whereas 0 of 17 were lost in patients without invasive cancer (P = 0.04). Only two adjuvant CTX programs were interrupted (3 and 6 weeks) by prosthetic complications, and one was delayed in onset by 1 week. RT to the reconstructed area was not associated with prosthetic loss or cosmetic problems. Thus, women may probably have IPMPBR and adjuvant therapies safely, if certain guidelines are followed.
NotesGA138 AMER SURG